PMID- 28614597
OWN - NLM
STAT- MEDLINE
DCOM- 20180702
LR  - 20210109
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 40
IP  - 10
DP  - 2017 Oct
TI  - ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of 
      quantitative contrast-enhanced CMR in intermediate-risk patients.
PG  - 853-860
LID - 10.1002/clc.22735 [doi]
AB  - BACKGROUND: Hypertrophic cardiomyopathy (HCM) remains the most common cause of 
      sudden cardiac death (SCD) in the young; however, current strategies do not 
      identify all HCM patients at risk. A novel validated algorithm was proposed by 
      the last European Society of Cardiology guidelines to guide implantable 
      cardioverter-defibrillator (ICD) therapy. Recently, extensive myocardial fibrosis 
      was independently associated with increased risk of SCD events. This study aimed 
      to establish the relation between myocardial fibrosis (late gadolinium 
      enhancement [LGE] extension) and the novel SCD risk-prediction model in a real 
      population of HCM to evaluate its potential additional value in the different 
      risk groups. HYPOTHESIS: There is a significant association between LGE extension 
      and the novel SCD risk calculator that may help conflicting ICD decisions. 
      METHODS: Seventy-seven patients with HCM underwent routine clinical evaluation, 
      echocardiography, and cardiac magnetic resonance study. Their SCD risk at 5 years 
      was calculated using the new model. RESULTS: Extension of LGE positively 
      correlated with SCD risk prediction (r = 0.7, P < 0.001). Low-, intermediate-, 
      and high-risk groups according to the model showed significantly different extent 
      of LGE (5% +/- 6% vs 18% +/- 9% vs 17% +/- 4%; P < 0.001). Four patients (6%) in the 
      low-risk group and 5 (62%) in the intermediate-risk group showed extensive areas 
      of LGE. All patients except 1 (86%) at highest risk (n = 6) showed extensive 
      areas of LGE. CONCLUSIONS: LGE extension is concordant with the novel SCD-risk 
      model defining low- and high-risk groups; it may provide additional information, 
      allowing better discrimination to support implantable cardioverter-defibrillator 
      decision. LGE quantification holds promise for SCD stratification in HCM.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Hinojar, Rocio
AU  - Hinojar R
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
AD  - Department of Medicine, University of Alcala, Madrid, Spain.
FAU - Zamorano, Jose Luis
AU  - Zamorano JL
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
AD  - Department of Medicine, University of Alcala, Madrid, Spain.
AD  - CIBERCV, Instituto de Salud Carlos III (ISCIII), Spain.
FAU - Gonzalez Gomez, Ariana
AU  - Gonzalez Gomez A
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
FAU - Plaza Martin, Maria
AU  - Plaza Martin M
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
FAU - Esteban, Amparo
AU  - Esteban A
AD  - Department of Radiology, University Hospital Ramon y Cajal, Madrid, Spain.
FAU - Rincon, Luis Miguel
AU  - Rincon LM
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
AD  - Department of Medicine, University of Alcala, Madrid, Spain.
AD  - CIBERCV, Instituto de Salud Carlos III (ISCIII), Spain.
FAU - Portugal, Juan Carlos
AU  - Portugal JC
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
AD  - Department of Cardiology, University Hospital Dr. Negrin, Gran Canaria, Spain.
FAU - Jimenez Nacher, Jose Julio
AU  - Jimenez Nacher JJ
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
FAU - Fernandez-Golfin, Covadonga
AU  - Fernandez-Golfin C
AD  - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
AD  - Department of Medicine, University of Alcala, Madrid, Spain.
AD  - CIBERCV, Instituto de Salud Carlos III (ISCIII), Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170614
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 1BJ477IO2L (gadobutrol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiomyopathy, Hypertrophic/complications/*diagnostic imaging/mortality/therapy
MH  - Clinical Decision-Making
MH  - Contrast Media/*administration & dosage
MH  - Death, Sudden, Cardiac/*etiology/prevention & control
MH  - *Decision Support Techniques
MH  - Defibrillators, Implantable
MH  - Echocardiography
MH  - Electric Countershock/instrumentation
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Middle Aged
MH  - Organometallic Compounds/*administration & dosage
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC6490362
OTO - NOTNLM
OT  - Cardiac Magnetic Resonance
OT  - Hypertrophic Cardiomyopathy
OT  - Late Gadolinium Enhancement
OT  - Risk Stratification
OT  - Sudden Cardiac Death
COIS- The authors declare no potential conflicts of interest.
EDAT- 2017/06/15 06:00
MHDA- 2018/07/03 06:00
PMCR- 2017/06/14
CRDT- 2017/06/15 06:00
PHST- 2017/03/09 00:00 [received]
PHST- 2017/04/28 00:00 [revised]
PHST- 2017/05/02 00:00 [accepted]
PHST- 2017/06/15 06:00 [pubmed]
PHST- 2018/07/03 06:00 [medline]
PHST- 2017/06/15 06:00 [entrez]
PHST- 2017/06/14 00:00 [pmc-release]
AID - CLC22735 [pii]
AID - 10.1002/clc.22735 [doi]
PST - ppublish
SO  - Clin Cardiol. 2017 Oct;40(10):853-860. doi: 10.1002/clc.22735. Epub 2017 Jun 14.